These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22191123)

  • 1. The proteasome as a target for prevention of restenosis following vascular injury.
    Ayub B; Mangalmurti S; Matsumura ME
    Vasa; 2011 Nov; 40(6):425-6. PubMed ID: 22191123
    [No Abstract]   [Full Text] [Related]  

  • 2. Intramural delivery of bortezomib inhibits restenosis following arterial injury.
    Gong X; Zhou Y
    Vasa; 2011 Nov; 40(6):449-52. PubMed ID: 22090177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of a proteasome in Pneumocystis carinii and its modulation by specific proteasome inhibitors.
    Tronconi E; Mazza F; Valerio A; Rinaudo MT; Piccinini M; Anselmino A; Cargnel A; Atzori C
    J Eukaryot Microbiol; 2006; 53 Suppl 1():S142-3. PubMed ID: 17169035
    [No Abstract]   [Full Text] [Related]  

  • 4. Selectively killing transformed cells through proteasome inhibition.
    Grant S
    Cell Cycle; 2009 Oct; 8(19):3074-5. PubMed ID: 19770579
    [No Abstract]   [Full Text] [Related]  

  • 5. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
    Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
    Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
    Gutman D; Morales AA; Boise LH
    Leukemia; 2009 Nov; 23(11):2181-3. PubMed ID: 19516276
    [No Abstract]   [Full Text] [Related]  

  • 9. Proteasome inhibition: mechanism of action.
    DeMartino GN
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
    Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
    Berkers CR; Verdoes M; Lichtman E; Fiebiger E; Kessler BM; Anderson KC; Ploegh HL; Ovaa H; Galardy PJ
    Nat Methods; 2005 May; 2(5):357-62. PubMed ID: 15846363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.
    Nakamura T; Tanaka K; Matsunobu T; Okada T; Nakatani F; Sakimura R; Hanada M; Iwamoto Y
    Int J Oncol; 2007 Oct; 31(4):803-11. PubMed ID: 17786311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.
    van der Heijden JW; Oerlemans R; Lems WF; Scheper RJ; Dijkmans BA; Jansen G
    Clin Exp Rheumatol; 2009; 27(1):92-8. PubMed ID: 19327235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
    Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
    Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells].
    Lu SF; Lu H; Shen WY; Zhang JF; Liu P; Wang YR; Wang LX; Yang H; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1006-9. PubMed ID: 18928584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
    Colland F
    IDrugs; 2006 Mar; 9(3):179-81. PubMed ID: 16523381
    [No Abstract]   [Full Text] [Related]  

  • 17. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
    Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
    Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib.
    Gerlach UA; Schoenemann C; Lachmann N; Koch M; Pascher A
    Transpl Int; 2011 May; 24(5):e43-5. PubMed ID: 21155900
    [No Abstract]   [Full Text] [Related]  

  • 19. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
    Cheriyath V; Jacobs BS; Hussein MA
    Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.
    Kloss A; Meiners S; Ludwig A; Dahlmann B
    Cardiovasc Res; 2010 Jan; 85(2):367-75. PubMed ID: 19564153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.